SG11202104966XA - Sustained local drug levels for innate immune agonists - Google Patents

Sustained local drug levels for innate immune agonists

Info

Publication number
SG11202104966XA
SG11202104966XA SG11202104966XA SG11202104966XA SG11202104966XA SG 11202104966X A SG11202104966X A SG 11202104966XA SG 11202104966X A SG11202104966X A SG 11202104966XA SG 11202104966X A SG11202104966X A SG 11202104966XA SG 11202104966X A SG11202104966X A SG 11202104966XA
Authority
SG
Singapore
Prior art keywords
innate immune
drug levels
local drug
sustained local
immune agonists
Prior art date
Application number
SG11202104966XA
Inventor
David B Rosen
Luis Zuniga
Juha Punnonen
Lars Holten-Andersen
Kennett Sprogøe
Yang Yang-Malten
Torben Lessmann
Nicola Bisek
Samuel Weisbrod
Sebastian Stark
Tobias Voigt
Original Assignee
Ascendis Pharma Oncology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Oncology Div A/S filed Critical Ascendis Pharma Oncology Div A/S
Publication of SG11202104966XA publication Critical patent/SG11202104966XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SG11202104966XA 2019-01-04 2020-01-03 Sustained local drug levels for innate immune agonists SG11202104966XA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19150388 2019-01-04
EP19181823 2019-06-21
EP19206471 2019-10-31
PCT/EP2020/050095 WO2020141222A1 (en) 2019-01-04 2020-01-03 Sustained local drug levels for innate immune agonists

Publications (1)

Publication Number Publication Date
SG11202104966XA true SG11202104966XA (en) 2021-06-29

Family

ID=69147693

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104966XA SG11202104966XA (en) 2019-01-04 2020-01-03 Sustained local drug levels for innate immune agonists

Country Status (12)

Country Link
US (1) US20220054476A1 (en)
EP (1) EP3906032A1 (en)
JP (1) JP2022516314A (en)
KR (1) KR20210113272A (en)
CN (1) CN113316452A (en)
AU (1) AU2020204785A1 (en)
BR (1) BR112021010043A2 (en)
CA (1) CA3125479A1 (en)
IL (1) IL284436A (en)
MX (1) MX2021007707A (en)
SG (1) SG11202104966XA (en)
WO (1) WO2020141222A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023110727A2 (en) * 2021-12-13 2023-06-22 Ascendis Pharma Oncology Division A/S Novel cancer treatments with tlr7/8 agonists

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
MX2009002859A (en) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Hindered ester-based biodegradable linkers for oligonucleotide delivery.
TW200922624A (en) 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery system containing a multi-substituted aromatic moiety
EP2596805B1 (en) 2008-02-01 2021-10-27 Ascendis Pharma A/S Prodrug comprising a drug-linker conjugate
WO2009143412A2 (en) 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
EP2459227B1 (en) 2009-07-31 2021-03-17 Ascendis Pharma A/S Prodrugs containing an aromatic amine connected by an amide bond to a carrier
BR112012002280B1 (en) 2009-07-31 2020-04-07 Ascendis Pharma As water-insoluble hydrogel based on biodegradable polyethylene glycol, its preparation process, conjugate, vehicle-bound compound and pharmaceutical composition.
CN102724967A (en) 2009-12-31 2012-10-10 安龙制药公司 Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
CN103025165B (en) 2010-05-05 2016-06-08 普罗林科斯有限责任公司 From the controlled release of macromolecular conjugates
CN103025164B (en) 2010-05-05 2017-03-08 普罗林科斯有限责任公司 The control release of medicine from solid support
CN103857413A (en) 2011-08-12 2014-06-11 阿森迪斯药物股份有限公司 Carrier-linked treprostinil prodrugs
AU2012296955B2 (en) 2011-08-12 2016-12-15 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
RU2014118642A (en) 2011-10-12 2015-11-20 Асцендис Фарма Офтальмолоджи Дивижн А/С PREVENTION AND TREATMENT OF EYE VIOLATIONS
CA2868925C (en) 2012-04-25 2020-01-21 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
AU2013328785B2 (en) 2012-10-11 2016-07-21 Ascendis Pharma A/S Hydrogel prodrugs
EP3193941A1 (en) 2014-08-06 2017-07-26 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
US10799563B2 (en) 2014-11-18 2020-10-13 Ascendis Pharma Endocrinology Division Polymeric hGH prodrugs
JP7216006B2 (en) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド Hydrogel Crosslinked Hyaluronic Acid Prodrug Compositions and Methods
AU2019246389A1 (en) 2018-03-28 2020-08-27 Ascendis Pharma Oncology Division A/S IL-2 conjugates

Also Published As

Publication number Publication date
US20220054476A1 (en) 2022-02-24
EP3906032A1 (en) 2021-11-10
WO2020141222A1 (en) 2020-07-09
MX2021007707A (en) 2021-08-05
KR20210113272A (en) 2021-09-15
BR112021010043A2 (en) 2021-10-26
CA3125479A1 (en) 2020-07-09
IL284436A (en) 2021-08-31
AU2020204785A1 (en) 2021-06-03
JP2022516314A (en) 2022-02-25
CN113316452A (en) 2021-08-27

Similar Documents

Publication Publication Date Title
HK1252836A1 (en) Drug delivery from hydrogels
ZA201802371B (en) Glucagon receptor agonists
IL257077B (en) Multiligand agent for drug delivery
HK1256138A1 (en) Bacteria-based protein delivery
ZA202001044B (en) Drug delivery composition
IL282684A (en) Conveyor system
PL3728083T3 (en) Teleskpic conveyor
IL292601A (en) Npy2 receptor agonists
GB201807040D0 (en) Drug delivery
IL280184A (en) Drug delivery devices
IL284436A (en) Sustained local drug levels for innate immune agonists
SG11202010804XA (en) Curved conveyor
GB201806932D0 (en) Conveyor
ZA201801222B (en) Conveyor pan
GB201805669D0 (en) Conveyor System
GB201721832D0 (en) Ocular drug delivery
GB201710280D0 (en) Drug delivery apparatus
IL275664A (en) Drug delivery system
PL3694585T3 (en) Drug delivery apparatus
GB201718346D0 (en) Shuffleboard platform
HU5077U (en) Conveyor side-mover
PL3581525T3 (en) Conveyor pan
GB201711779D0 (en) Delivery
GB201707035D0 (en) Drug delivery composition
GB201706968D0 (en) Drug delivery composition